BioSpace News Archive

Viracta Therapeutics, Inc. (Nasdaq: VIRX), and XOMA Corporation (NASDAQ: XOMA) announced today XOMA has purchased the potential future milestones and royalties associated with existing licenses relating to two clinical-stage drug candidates that were obtained in Viracta’s merger with Sunesis Pharmaceuticals in exchange for an upfront payment of $13.5 million

Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, today announced $35 million in Series C Preferred Stock funding led by Paragon Biosciences. Fidelity Management & Research Company LLC and Valor Equity Partners joined the round.

March 22 through March 28, 2021 is National Drug and Alcohol Facts Week®, an annual, week-long, health observance developed by the National Institute on Drug Abuse to raise awareness about substance abuse, including alcohol, and addiction in communities across the U.S.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002 , a novel therapeutic targeted for the treatment of COVID-19 .

- Milestone represents the first patient dosed with an OTS AdenoVerse immunotherapy targeting infectious disease - - RRP is a rare, difficult-to-treat neoplastic disease caused by HPV 6 or HPV 11 and currently has no proven effective systemic therapy -

BIOQuébec, Québec’s largest network of biotechnologies and life sciences, and BioForward Wisconsin, the collective voice of Wisconsin’s robust and comprehensive biohealth cluster, will sign a memorandum of understanding to advance cooperative relationships and promote life sciences.

Ended Q4 with cash, cash equivalents, restricted cash and investments of $105.3 million, sufficient to fund operations through potential FUROSCIX approval and launch, if approved, and into 2023

The SERIES-5 MyoVision is an FDA-cleared, Class II medical device patented for diagnosing soft tissue injury.

EpiSwitch® CST is a highly accurate prognostic test that predicts personalized risk of severe illness due to SARS-CoV-2 virus

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Rajiv Shukla, Alpha Healthcare Acquisition Corp. Chairman and CEO, will participate in a panel discussion at the Council for Entrepreneurial Development (CED) Venture Connect 2021 Summit taking place virtually March 23-25,